ストックスクリーナーアプリを入手
9.79
0.71%
-0.07
プレマーケット:
9.62
-0.17
-1.74%
前日終値:
$9.86
開ける：
$9.79
24時間の取引高:
786.04K
Relative Volume:
0.78
時価総額：
$1.58B
収益：
-
当期純損益:
$-274.18M
株価収益率:
-5.6978
EPS:
-1.7182
ネットキャッシュフロー:
$-198.33M
1週間 パフォーマンス:
-9.14%
1か月 パフォーマンス:
-40.63%
6か月 パフォーマンス:
+1.03%
1年 パフォーマンス:
-17.38%
1日の値動き範囲:
$9.62
$10.09
1週間の範囲:
$9.34
$11.97
52週間の値動き範囲:
$8.33
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
名前
Neumora Therapeutics Inc
セクター
電話
(857) 760-0900
住所
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| NMRA | 9.79 | 1.58B | 0 | -274.18M | -198.33M | -1.7182 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-10-10 | 開始されました | BofA Securities | Buy |
| 2023-10-10 | 開始されました | Guggenheim | Buy |
| 2023-10-10 | 開始されました | JP Morgan | Overweight |
| 2023-10-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-10 | 開始されました | Stifel | Buy |
| 2023-10-10 | 開始されました | William Blair | Outperform |
すべてを表示
Neumora Therapeutics Inc (NMRA) 最新ニュース
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode - MSN
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for NMRA Issued By William Blair - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat
Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat
JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK
Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
(NMRA) On The My Stocks Page - Stock Traders Daily
Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World
SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat
Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India
Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLC - MarketBeat
(NMRA) Investment Analysis - Stock Traders Daily
This trade activity should not be overlooked: Neumora Therapeutics Inc. (NMRA) - SETE News
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider Selling - Defense World
Have you been able to find a good deal on Neumora Therapeutics Inc.’s shares? - US Post News
Neumora Therapeutics Inc (NMRA) 財務データ
収益
当期純利益
現金流量
EPS
Neumora Therapeutics Inc (NMRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fust Matthew K | Director |
Oct 17 '24 |
Option Exercise |
6.81 |
7,739 |
52,730 |
27,839 |
| Fust Matthew K | Director |
Oct 18 '24 |
Sale |
17.03 |
14,049 |
239,319 |
20,100 |
| Fust Matthew K | Director |
Oct 17 '24 |
Sale |
17.01 |
7,739 |
131,643 |
20,100 |
0.69%
6.90%
大文字化:
|
ボリューム (24 時間):